 | • レポートコード：QYR2104Z4961 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、93ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品、ヘルスケア |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、組換え治療用抗体＆タンパク質のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（血漿タンパク質、融合タンパク質、モノクローナル抗体、ホルモン、酵素、凝固因子、その他）、用途別市場規模（腫瘍、血液、免疫、内分泌、感染症、循環器疾患、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・組換え治療用抗体＆タンパク質の市場動向 ・企業の競争状況、市場シェア ・組換え治療用抗体＆タンパク質の種類別市場規模（血漿タンパク質、融合タンパク質、モノクローナル抗体、ホルモン、酵素、凝固因子、その他） ・組換え治療用抗体＆タンパク質の用途別市場規模（腫瘍、血液、免疫、内分泌、感染症、循環器疾患、その他） ・組換え治療用抗体＆タンパク質の北米市場規模2016-2027（アメリカ、カナダ） ・組換え治療用抗体＆タンパク質のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・組換え治療用抗体＆タンパク質のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・組換え治療用抗体＆タンパク質の中南米市場規模2016-2027（メキシコ、ブラジル） ・組換え治療用抗体＆タンパク質の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Abbott、Amgen、Biogen、Eli Lilly、Roche、Johnson and Johnson、Merck、Novo Nordisk、Pfizer、Sanofi） ・結論 |
Therapeutic proteins are engineered in the laboratory for pharmaceutical use, including non-covalent binders. These proteins are highly effective and serve as modernized treatment for rare as well as chronic diseases. Protein therapeutics offer custom-made treatment approach by supporting a specifically targeted therapeutic process by compensating the deficiency of an essential protein. Recombinant proteins have gained significant traction for therapeutic applications and the number of proteins either launched or approved into clinical trials has continually increased over the past two decades. According to the National Center for Biotechnology Information (NCBI) data of 2017, the U.S. Food and Drug Administration (FDA) approved over 140 recombinant therapeutic proteins for human use and several hundred are currently in development. Majority of these proteins are recombinant monoclonal antibodies.
The global recombinant therapeutic antibodies and proteins market size was valued at US$ 92.5 billion in 2017, and is expected to witness a robust CAGR of 11.2% over the forecast period (2017 – 2025).
Market Analysis and Insights: Global Recombinant Therapeutic Antibodies and Proteins Market
The global Recombinant Therapeutic Antibodies and Proteins market size is projected to reach US$ 143680 million by 2026, from US$ 89490 million in 2019, at a CAGR of 6.9% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Recombinant Therapeutic Antibodies and Proteins market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Recombinant Therapeutic Antibodies and Proteins market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Recombinant Therapeutic Antibodies and Proteins market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Recombinant Therapeutic Antibodies and Proteins market.
Global Recombinant Therapeutic Antibodies and Proteins Scope and Market Size
Recombinant Therapeutic Antibodies and Proteins market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Recombinant Therapeutic Antibodies and Proteins market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Plasma Protein
Fusion Proteins
Monoclonal Antibodies
Hormones
Enzyme
Coagulation Factors
Others
Segment by Application
Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Disease
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Abbott
Amgen
Biogen
Eli Lilly
Roche
Johnson and Johnson
Merck
Novo Nordisk
Pfizer
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Recombinant Therapeutic Antibodies and Proteins Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Plasma Protein
1.2.3 Fusion Proteins
1.2.4 Monoclonal Antibodies
1.2.5 Hormones
1.2.6 Enzyme
1.2.7 Coagulation Factors
1.2.8 Others
1.3 Market by Application
1.3.1 Global Recombinant Therapeutic Antibodies and Proteins Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Oncology
1.3.3 Hematology
1.3.4 Immunology
1.3.5 Endocrinology
1.3.6 Infectious Disease
1.3.7 Cardiovascular Disease
1.3.8 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Recombinant Therapeutic Antibodies and Proteins Market Perspective (2016-2027)
2.2 Recombinant Therapeutic Antibodies and Proteins Growth Trends by Regions
2.2.1 Recombinant Therapeutic Antibodies and Proteins Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Recombinant Therapeutic Antibodies and Proteins Historic Market Share by Regions (2016-2021)
2.2.3 Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Regions (2022-2027)
2.3 Recombinant Therapeutic Antibodies and Proteins Industry Dynamic
2.3.1 Recombinant Therapeutic Antibodies and Proteins Market Trends
2.3.2 Recombinant Therapeutic Antibodies and Proteins Market Drivers
2.3.3 Recombinant Therapeutic Antibodies and Proteins Market Challenges
2.3.4 Recombinant Therapeutic Antibodies and Proteins Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Recombinant Therapeutic Antibodies and Proteins Players by Revenue
3.1.1 Global Top Recombinant Therapeutic Antibodies and Proteins Players by Revenue (2016-2021)
3.1.2 Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share by Players (2016-2021)
3.2 Global Recombinant Therapeutic Antibodies and Proteins Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Recombinant Therapeutic Antibodies and Proteins Revenue
3.4 Global Recombinant Therapeutic Antibodies and Proteins Market Concentration Ratio
3.4.1 Global Recombinant Therapeutic Antibodies and Proteins Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recombinant Therapeutic Antibodies and Proteins Revenue in 2020
3.5 Recombinant Therapeutic Antibodies and Proteins Key Players Head office and Area Served
3.6 Key Players Recombinant Therapeutic Antibodies and Proteins Product Solution and Service
3.7 Date of Enter into Recombinant Therapeutic Antibodies and Proteins Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Recombinant Therapeutic Antibodies and Proteins Breakdown Data by Type
4.1 Global Recombinant Therapeutic Antibodies and Proteins Historic Market Size by Type (2016-2021)
4.2 Global Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Type (2022-2027)
5 Recombinant Therapeutic Antibodies and Proteins Breakdown Data by Application
5.1 Global Recombinant Therapeutic Antibodies and Proteins Historic Market Size by Application (2016-2021)
5.2 Global Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Recombinant Therapeutic Antibodies and Proteins Market Size (2016-2027)
6.2 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Type
6.2.1 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2016-2021)
6.2.2 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2022-2027)
6.2.3 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2016-2027)
6.3 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Application
6.3.1 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2016-2021)
6.3.2 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2022-2027)
6.3.3 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2016-2027)
6.4 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Country
6.4.1 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2016-2021)
6.4.2 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Recombinant Therapeutic Antibodies and Proteins Market Size (2016-2027)
7.2 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Type
7.2.1 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2016-2021)
7.2.2 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2022-2027)
7.2.3 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2016-2027)
7.3 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Application
7.3.1 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2016-2021)
7.3.2 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2022-2027)
7.3.3 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2016-2027)
7.4 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Country
7.4.1 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2016-2021)
7.4.2 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size (2016-2027)
8.2 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Type
8.2.1 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2016-2027)
8.3 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Application
8.3.1 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2016-2027)
8.4 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Region
8.4.1 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size (2016-2027)
9.2 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Type
9.2.1 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2016-2021)
9.2.2 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2022-2027)
9.2.3 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2016-2027)
9.3 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Application
9.3.1 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2016-2021)
9.3.2 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2022-2027)
9.3.3 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2016-2027)
9.4 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Country
9.4.1 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2016-2021)
9.4.2 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size (2016-2027)
10.2 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Type
10.2.1 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2016-2027)
10.3 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Application
10.3.1 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2016-2027)
10.4 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Country
10.4.1 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Abbott
11.1.1 Abbott Company Details
11.1.2 Abbott Business Overview
11.1.3 Abbott Recombinant Therapeutic Antibodies and Proteins Introduction
11.1.4 Abbott Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
11.1.5 Abbott Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Recombinant Therapeutic Antibodies and Proteins Introduction
11.2.4 Amgen Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
11.2.5 Amgen Recent Development
11.3 Biogen
11.3.1 Biogen Company Details
11.3.2 Biogen Business Overview
11.3.3 Biogen Recombinant Therapeutic Antibodies and Proteins Introduction
11.3.4 Biogen Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
11.3.5 Biogen Recent Development
11.4 Eli Lilly
11.4.1 Eli Lilly Company Details
11.4.2 Eli Lilly Business Overview
11.4.3 Eli Lilly Recombinant Therapeutic Antibodies and Proteins Introduction
11.4.4 Eli Lilly Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
11.4.5 Eli Lilly Recent Development
11.5 Roche
11.5.1 Roche Company Details
11.5.2 Roche Business Overview
11.5.3 Roche Recombinant Therapeutic Antibodies and Proteins Introduction
11.5.4 Roche Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
11.5.5 Roche Recent Development
11.6 Johnson and Johnson
11.6.1 Johnson and Johnson Company Details
11.6.2 Johnson and Johnson Business Overview
11.6.3 Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Introduction
11.6.4 Johnson and Johnson Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
11.6.5 Johnson and Johnson Recent Development
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Recombinant Therapeutic Antibodies and Proteins Introduction
11.7.4 Merck Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
11.7.5 Merck Recent Development
11.8 Novo Nordisk
11.8.1 Novo Nordisk Company Details
11.8.2 Novo Nordisk Business Overview
11.8.3 Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Introduction
11.8.4 Novo Nordisk Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
11.8.5 Novo Nordisk Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Recombinant Therapeutic Antibodies and Proteins Introduction
11.9.4 Pfizer Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
11.9.5 Pfizer Recent Development
11.10 Sanofi
11.10.1 Sanofi Company Details
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Recombinant Therapeutic Antibodies and Proteins Introduction
11.10.4 Sanofi Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
11.10.5 Sanofi Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Recombinant Therapeutic Antibodies and Proteins Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Plasma Protein
Table 3. Key Players of Fusion Proteins
Table 4. Key Players of Monoclonal Antibodies
Table 5. Key Players of Hormones
Table 6. Key Players of Enzyme
Table 7. Key Players of Coagulation Factors
Table 8. Key Players of Others
Table 9. Global Recombinant Therapeutic Antibodies and Proteins Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Recombinant Therapeutic Antibodies and Proteins Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 11. Global Recombinant Therapeutic Antibodies and Proteins Market Size by Regions (2016-2021) & (US$ Million)
Table 12. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Regions (2016-2021)
Table 13. Global Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 14. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Regions (2022-2027)
Table 15. Recombinant Therapeutic Antibodies and Proteins Market Trends
Table 16. Recombinant Therapeutic Antibodies and Proteins Market Drivers
Table 17. Recombinant Therapeutic Antibodies and Proteins Market Challenges
Table 18. Recombinant Therapeutic Antibodies and Proteins Market Restraints
Table 19. Global Recombinant Therapeutic Antibodies and Proteins Revenue by Players (2016-2021) & (US$ Million)
Table 20. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Players (2016-2021)
Table 21. Global Top Recombinant Therapeutic Antibodies and Proteins Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recombinant Therapeutic Antibodies and Proteins as of 2020)
Table 22. Ranking of Global Top Recombinant Therapeutic Antibodies and Proteins Companies by Revenue (US$ Million) in 2020
Table 23. Global 5 Largest Players Market Share by Recombinant Therapeutic Antibodies and Proteins Revenue (CR5 and HHI) & (2016-2021)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Recombinant Therapeutic Antibodies and Proteins Product Solution and Service
Table 26. Date of Enter into Recombinant Therapeutic Antibodies and Proteins Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2016-2021) (US$ Million)
Table 29. Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share by Type (2016-2021)
Table 30. Global Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 31. Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 32. Global Recombinant Therapeutic Antibodies and Proteins Market Size Share by Application (2016-2021) & (US$ Million)
Table 33. Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share by Application (2016-2021)
Table 34. Global Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 35. Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 36. North America Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2016-2021) (US$ Million)
Table 37. North America Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2022-2027) & (US$ Million)
Table 38. North America Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2016-2021) (US$ Million)
Table 39. North America Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2022-2027) & (US$ Million)
Table 40. North America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2016-2021) & (US$ Million)
Table 41. North America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2022-2027) & (US$ Million)
Table 42. Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2016-2021) (US$ Million)
Table 43. Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2022-2027) & (US$ Million)
Table 44. Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2016-2021) (US$ Million)
Table 45. Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2022-2027) & (US$ Million)
Table 46. Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2016-2021) & (US$ Million)
Table 47. Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2016-2021) (US$ Million)
Table 49. Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2016-2021) (US$ Million)
Table 51. Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2022-2027) & (US$ Million)
Table 52. Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Region (2016-2021) & (US$ Million)
Table 53. Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Region (2022-2027) & (US$ Million)
Table 54. Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2016-2021) (US$ Million)
Table 55. Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2022-2027) & (US$ Million)
Table 56. Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2016-2021) (US$ Million)
Table 57. Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2022-2027) & (US$ Million)
Table 58. Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2016-2021) & (US$ Million)
Table 59. Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2016-2021) (US$ Million)
Table 61. Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2016-2021) (US$ Million)
Table 63. Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2022-2027) & (US$ Million)
Table 64. Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2016-2021) & (US$ Million)
Table 65. Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2022-2027) & (US$ Million)
Table 66. Abbott Company Details
Table 67. Abbott Business Overview
Table 68. Abbott Recombinant Therapeutic Antibodies and Proteins Product
Table 69. Abbott Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021) & (US$ Million)
Table 70. Abbott Recent Development
Table 71. Amgen Company Details
Table 72. Amgen Business Overview
Table 73. Amgen Recombinant Therapeutic Antibodies and Proteins Product
Table 74. Amgen Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021) & (US$ Million)
Table 75. Amgen Recent Development
Table 76. Biogen Company Details
Table 77. Biogen Business Overview
Table 78. Biogen Recombinant Therapeutic Antibodies and Proteins Product
Table 79. Biogen Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021) & (US$ Million)
Table 80. Biogen Recent Development
Table 81. Eli Lilly Company Details
Table 82. Eli Lilly Business Overview
Table 83. Eli Lilly Recombinant Therapeutic Antibodies and Proteins Product
Table 84. Eli Lilly Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021) & (US$ Million)
Table 85. Eli Lilly Recent Development
Table 86. Roche Company Details
Table 87. Roche Business Overview
Table 88. Roche Recombinant Therapeutic Antibodies and Proteins Product
Table 89. Roche Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021) & (US$ Million)
Table 90. Roche Recent Development
Table 91. Johnson and Johnson Company Details
Table 92. Johnson and Johnson Business Overview
Table 93. Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Product
Table 94. Johnson and Johnson Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021) & (US$ Million)
Table 95. Johnson and Johnson Recent Development
Table 96. Merck Company Details
Table 97. Merck Business Overview
Table 98. Merck Recombinant Therapeutic Antibodies and Proteins Product
Table 99. Merck Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021) & (US$ Million)
Table 100. Merck Recent Development
Table 101. Novo Nordisk Company Details
Table 102. Novo Nordisk Business Overview
Table 103. Novo Nordisk Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021) & (US$ Million)
Table 104. Novo Nordisk Recent Development
Table 105. Pfizer Company Details
Table 106. Pfizer Business Overview
Table 107. Pfizer Recombinant Therapeutic Antibodies and Proteins Product
Table 108. Pfizer Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021) & (US$ Million)
Table 109. Pfizer Recent Development
Table 110. Sanofi Company Details
Table 111. Sanofi Business Overview
Table 112. Sanofi Recombinant Therapeutic Antibodies and Proteins Product
Table 113. Sanofi Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021) & (US$ Million)
Table 114. Sanofi Recent Development
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Type: 2020 VS 2027
Figure 2. Plasma Protein Features
Figure 3. Fusion Proteins Features
Figure 4. Monoclonal Antibodies Features
Figure 5. Hormones Features
Figure 6. Enzyme Features
Figure 7. Coagulation Factors Features
Figure 8. Others Features
Figure 9. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Application: 2020 VS 2027
Figure 10. Oncology Case Studies
Figure 11. Hematology Case Studies
Figure 12. Immunology Case Studies
Figure 13. Endocrinology Case Studies
Figure 14. Infectious Disease Case Studies
Figure 15. Cardiovascular Disease Case Studies
Figure 16. Others Case Studies
Figure 17. Recombinant Therapeutic Antibodies and Proteins Report Years Considered
Figure 18. Global Recombinant Therapeutic Antibodies and Proteins Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 19. Global Recombinant Therapeutic Antibodies and Proteins Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 20. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Regions: 2020 VS 2027
Figure 21. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Regions (2022-2027)
Figure 22. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Players in 2020
Figure 23. Global Top Recombinant Therapeutic Antibodies and Proteins Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recombinant Therapeutic Antibodies and Proteins as of 2020
Figure 24. The Top 10 and 5 Players Market Share by Recombinant Therapeutic Antibodies and Proteins Revenue in 2020
Figure 25. Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share by Type (2016-2021)
Figure 26. Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share by Type (2022-2027)
Figure 27. North America Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. North America Recombinant Therapeutic Antibodies and Proteins Market Share by Type (2016-2027)
Figure 29. North America Recombinant Therapeutic Antibodies and Proteins Market Share by Application (2016-2027)
Figure 30. North America Recombinant Therapeutic Antibodies and Proteins Market Share by Country (2016-2027)
Figure 31. United States Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Canada Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Europe Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Europe Recombinant Therapeutic Antibodies and Proteins Market Share by Type (2016-2027)
Figure 35. Europe Recombinant Therapeutic Antibodies and Proteins Market Share by Application (2016-2027)
Figure 36. Europe Recombinant Therapeutic Antibodies and Proteins Market Share by Country (2016-2027)
Figure 37. Germany Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. France Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. U.K. Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Italy Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Russia Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Nordic Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Share by Type (2016-2027)
Figure 45. Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Share by Application (2016-2027)
Figure 46. Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Share by Region (2016-2027)
Figure 47. China Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Japan Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. South Korea Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Southeast Asia Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. India Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Australia Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Latin America Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Latin America Recombinant Therapeutic Antibodies and Proteins Market Share by Type (2016-2027)
Figure 55. Latin America Recombinant Therapeutic Antibodies and Proteins Market Share by Application (2016-2027)
Figure 56. Latin America Recombinant Therapeutic Antibodies and Proteins Market Share by Country (2016-2027)
Figure 57. Mexico Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Brazil Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Share by Type (2016-2027)
Figure 61. Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Share by Application (2016-2027)
Figure 62. Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Share by Country (2016-2027)
Figure 63. Turkey Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 64. Saudi Arabia Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 65. UAE Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 66. Abbott Revenue Growth Rate in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
Figure 67. Amgen Revenue Growth Rate in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
Figure 68. Biogen Revenue Growth Rate in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
Figure 69. Eli Lilly Revenue Growth Rate in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
Figure 70. Roche Revenue Growth Rate in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
Figure 71. Johnson and Johnson Revenue Growth Rate in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
Figure 72. Merck Revenue Growth Rate in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
Figure 73. Novo Nordisk Revenue Growth Rate in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
Figure 74. Pfizer Revenue Growth Rate in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
Figure 75. Sanofi Revenue Growth Rate in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed
世界の組換えタンパク質市場規模・現状・予測（2021年-2027年） Recombinant protein is a manipulated form of protein encoded by recombinant DNA, which has been cloned in a foreign expression system to supports the expression of the exogenous gene. This recombinant DNA construct can be used to manufacture large quantities of useful protein products. The recombina…- 世界の組換え非グリコシル化タンパク質バイオシミラー市場規模・現状・予測（2021年-2027年） Recombinant non-glycosylated proteins include human growth hormone, granulocyte colony-stimulating factor, interferons, and insulin. The statistic scope in this report is Recombinant non-glycosylated proteins biosimilars. Market Analysis and Insights: Global Recombinant Non-Glycosylated Proteins Bio…
- 世界のIGYポリクローナル抗体市場規模・現状・予測（2021年-2027年） Immunoglobulin Y (abbreviated as IgY) is a type of immunoglobulin which is the major antibody in bird, reptile, and lungfish blood. It is also found in high concentrations in chicken egg yolk. As with the other immunoglobulins, IgY is a class of proteins which are formed by the immune system in reac…
- 世界のCD38モノクローナル抗体市場規模・現状・予測（2021年-2027年） CD38 monoclonal antibodies target the CD38 surface antigen(sAg) of hematopoietic cells, which is important for cell function. Once CD38 monoclonal antibodies bind to the antigen it inhibits tumour growth by interrupting CD38 functions and causes cell death. CD38 monoclonal antibodies are used to tre…
- 世界のレクティス（炭水化物結合タンパク質）市場 2021：企業別、地域別、種類・用途別 The Lectis(Carbohydrate Binding Proteins) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization,…